Frankfurt am Main, 24. July 2020 – The leading independent commercial law firm Oppenhoff advised the family owners of CNP on the sale of all group companies of the pharmaceutical group to the private equity investor capiton AG.
The acquisition is being made in together with the management team and experienced industry experts. The parties agreed not to disclose the purchase price. The transaction is still subject to merger control clearance.
CNP Group is an international manufacturer and distributor of generic pharmaceuticals with a focus on anti-infectives. In addition to antibiotics, CNP offers over-the-counter drugs and medical devices. Most of the products are manufactured at the company's two production sites in Saarland. With ca. 400 marketing authorizations and about 250 employees, CNP Group generates sales of more than € 40 million in 19 countries.
Capiton AG is an independent, owner-managed private equity company that manages a total fund volume of over € 1 billion. The investment portfolio of capiton AG currently comprises 13 medium-sized companies.
Led by Dr. Markus Rasner, an Oppenhoff team advised the owners of CNP Group on all legal aspects of the transaction. Oppenhoff was thus once again involved as adviser on a transaction in the pharmaceutical sector. Further Oppenhoff team members were Marcel Markovic (M&A), Moritz Schmitz (M&A and pharmaceuticals), Peter Klappich (pharmaceuticals), Anja Dombrowsky, Cornelia-Cristina Scupra (both labor), Dr. Jürgen Hartung (IT and data protection), Georg Lecheler, Nicolas Degen (both IP), Marvin Rochner (real estate), Dr. Gunnar Knorr (taxes) and Dr. Simon Spangler (antitrust). In addition, the Oppenhoff team managed transaction cross-border and was supported by Kambourov & Partners (Bulgaria), Wardynski & Partners (Poland) and BDK Advokati (Serbia), among others.